DRNA - Novo Nordisk selects first development candidate under Dicerna pact

Dicerna Pharmaceuticals (DRNA) +4% in premarket as its collaborating partner Novo Nordisk (NVO) has nominated its first candidate under the existing agreement, for the discovery and development of therapies for the treatment of liver-related cardiometabolic diseases using Dicerna’s proprietary GalXC RNAi platform technology. The event triggers $2.5M milestone payment to Dicerna.Dicerna also earned $25M annual fee for delivery of multiple GalXC RNAi Molecules in 2020.The collaboration announced in November 2019, intends to explore more than 30 liver cell targets and may deliver multiple clinical candidates.

For further details see:

Novo Nordisk selects first development candidate under Dicerna pact